申请人:Norwich Eaton Pharmaceuticals, Inc.
公开号:EP0251380A2
公开(公告)日:1988-01-07
The present invention involves 2-(5-phenyl-2-furanyl)-imidazoles conforming to the chemical structure:wherein R¹ is mono- or di- substituents selected from the group consisting of hydrogen, halo, nitro, trifluoromethyl, straight and branched chain C₁-C₅ alkyl, acetyl, propionyl, methoxy and ethoxy; and R² is mono- or di- substituents selected from the group consisting of hydrogen, methyl, and ethyl; and pharmaceutically acceptable salts and/or hydrates thereof, pharmaceutical compositions containing such compounds, and methods for enhancing the contractile force of cardiac muscle of a mammal which comprises systemically administering such compounds to a mammal.
本发明涉及符合以下化学结构的 2-(5-苯基-2-呋喃基)-咪唑:其中 R¹ 是选自氢、卤素、硝基、三氟甲基、直链和支链 C₁-C₅烷基、乙酰基、丙酰基、甲氧基和乙氧基组成的组的单取代基或双取代基;R² 是选自氢、甲基和乙基组成的组的单取代基或双取代基;以及其药学上可接受的盐和/或水合物、含有此类化合物的药物组合物和增强哺乳动物心肌收缩力的方法,其中包括向哺乳动物全身施用此类化合物。